Clinical Trial

Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory/resistant or steroid-dependent GVHD.
Trial Details
NCT Number NCT06568328
Lead Sponsor Fujian Medical University
Conditions Graft vs Host Disease
Enrollment 17 participants
Start Date 2024-09-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-23